Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE: Mepolizumab for Clinical Remission in Severe Asthma
NCT06041386Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 4 trial of mepolizumab in asthma, sponsored by GSK. Started Mar 2024; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06041386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041386.